Date:
12^th May 2015

Venue:
Education Centre, The Christie NHS Foundation Trust, Manchester

Course description:

This course covers a wide range of licensed and experimental cancer treatments, explaining their mechanism of action at a molecular and cellular level. It also contains detailed information on mechanisms of drug resistance and discusses the future of personalised cancer medicine.

Topics Covered and Learning Outcomes:

• Faulty cell communication and other hallmarks of cancer cells as drug targets.
• Treatments that target: receptor tyrosine kinases, B-Raf, mTOR, MEK, angiogenesis, HSP9O, hedgehog signalling, PARP etc.
• Experimental approaches such as immunotherapy, RNA interference and cancer-killing viruses.
• The challenges and changes in clinical trial design.
• The use of biomarkers to select patients for trials and treatments.

By the end of the course delegates will be able to:

• Describe the mechanism of action of a wide range of targeted cancer treatments.
• Understand much of the jargon and scientific terminology used in relation to these treatments.
• Appreciate some of the challenges in creating new treatments and testing them in clinical trials.
• Understand the promise and limitations of personalised cancer therapy.

Targeted Audience:

Experienced research nurses and clinical trials staff with a biology background.

Course Fee:

NHS Fee: £100.00
Non-NHS Fee: £200.00